Allermi, a San Francisco, CA-based direct-to-consumer telehealth service, raised $3.5M in Seed funding.
The round was led by Nelstone Ventures, and FourSight Capital Partners.
The company intends to use the funds to continue national expansion; build and scale business, marketing and product operations; and enlarge marketing channels.
RELATED: Autism care platform SpectrumAi scores $20M
Led by CEO Shani Bocian, Allermi is a direct-to-consumer telehealth service providing a customized approach to allergy relief.
Dr. Robert Bocian is an allergist for more than 30 years, associate professor of allergy-immunology at Stanford and inventor of Bocian’s Potions, the custom approach offered by Allermi that combines and adjusts the doses of multiple clinically-proven medications into one nasal spray bottle to address patients’ specific symptoms.
After completing an online questionnaire that is then evaluated by an Allermi physician, patients are prescribed a customized nasal spray containing up to four active medication ingredients, combined and dosed for each patient’s unique symptoms and severity.
Delivered by mail on a monthly or on-demand basis, each patient receives a personalized treatment plan, along with access to a dedicated care team which patients can contact for ongoing support.
Allermi is currently available to residents 18 or older in 28 states including: Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois, Iowa, Kentucky, Massachusetts, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Mexico, New York, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Vermont and Washington.
